Compound sitagliptin-metformin: a new antidabetic agent for type 2 diabetesZHANG Rui-xue1833-1835,1839
Comparative analysis of the innovative drug monitoring period system between China and JapanDING Jin-xi, LI Yuan, WANG Ying-wei1840-1845
Technical requirement on nonclinical evaluation of fixed combinations from European Medicines AgencyGUANG Hong-mei, WANG Qing-li1846-1848
The US generic drug industry: lessons from the first 25 yearsGarth Boehm, YAO Li-xin, HAN Liang, ZHENG Qiang1849-1860
Considerations for strengthening the supervision on clinical trials of vaccine in China ( Part Ⅰ )GAO Rong, LI Jian-ming1861-1863
Pharmacokinetics of recombinant lysostaphin in burned patientsYANG Fei-fei, XIONG Yu-qing, XIA Chun-hua, MO Yun-jie, ZHANG Ji-en, LI Guo-dong, LU Wan-ying, HUANG Qing-shan1864-1866,1877
Significance of mitochondrial toxicity testing in the safety evaluation of innovative drugsGUO Jia-bin, PENG Hui, WANG Yi-mei, PENG Shuang-qing1867-1871
Gas chromatography detection of residual solvents in torasemideLIU Ming-li, WEI Ning-yi, ZHOU Ying, MA Shuang-cheng1872-1873,1883
Analysis and discussion on 2010 edition (volume Ⅰ) of Chinese PharmacopoeiaCAI Xiao-bing, HU Xin, JIN Peng-fei1874-1877